Us Fda Approves Two Opdivo-Based Regimens As First-Line Treatments For Unresectable Advanced Or Metastatic Escc

Us Fda Approves Two Opdivo-Based Regimens As First-Line Treatments For Unresectable Advanced Or Metastatic Escc

By, Admin 31 May 2022

Bristol Myers Squibb Announced That The Us Food And Drug Administration (Fda) Has Approved Both Opdivo (Nivolumab) (Injection For Intravenous Use) In Combination With Fluoropyrimidine- And Platinum-Containing Chemotherapy And Opdivo Plus Yervoy (Ipilimumab) As A First-Line Treatment For Adult Patients With Unresectable Advanced Or Metastatic Esophageal Squamous Cell Carcinoma (Escc) Regardless Of Pd-L1 Status.The Approvals Are Based On The Phase 3 Checkmate -648 Trial, Which Evaluated Opdivo In Combination With Chemotherapy (N=321) And Opdivo Plus Yervoy (N=325) Each Compared To Chemotherapy Alone (N=324), And Was The Largest Phase 3 Trial Of An Immunotherapy In First-Line Escc.In The Trial, Opdivo In Combination With Chemotherapy Demonstrated Superior Overall Survival (Os) Compared To Chemotherapy Alone, Both In All Randomized Patients, A Secondary Endpoint, Which Was Hierarchically Tested (Hazard Ratio [Hr] 0.74, 95% Confidence Interval [Ci]: 0.61 To 0.90, P=0.0021) And In Patients Whose Tumours Express Pd-L1 (=1%), A Primary Endpoint (Hr 0.54, 95% Ci: 0.41 To 0.71, P<0.0001). In All Randomized Patients The Median Os (Mos) Was 13.2 Months (95% Ci: 11.1 To 15.7) With Opdivo In Combination With Chemotherapy Versus 10.7 Months (95% Ci: 9.4 To 11.9) With Chemotherapy Alone.1 In Patients Whose Tumours Express Pd-L1 (=1%) The Mos Was 15.4 Months (95% Ci: 11.9 To 19.5) For Opdivo In Combination With Chemotherapy Versus 9.1 Months (95% Ci: 7.7 To 10) With Chemotherapy Alone.1 The Median Progression-Free Survival (Pfs) In All Randomized Patients, Which Was A Hierarchically Tested Secondary Endpoint, Was 5.8 Months (95% Ci: 5.6 To 7.0) For Opdivo In Combination With Chemotherapy And 5.6 Months (95% Ci: 4.3 To 5.9) For Chemotherapy Alone (Hr= 0.81; 95% Ci: 0.67 To 0.99, P=Not Significant). Per Pre-Specified Analysis, Pfs Did Not Meet Statistical Significance. The Median Pfs In Patients Whose Tumours Express Pd-L1 (=1%), Which Was A Co-Primary Endpoint, Was 6.9 Months (95% Ci: 5.7 To 8.3) For Opdivo In Combination With Chemotherapy And 4.4 Months (95% Ci: 2.9 To 5.8) For Chemotherapy Alone (Hr 0.65; 95% Ci: 0.49 To 0.86, P=0.0023).Opdivo Plus Yervoy Also Improved Os Compared To Chemotherapy In All-Randomized Patients, A Secondary Endpoint, Which Was Hierarchically Tested (Hr 0.78, 95% Ci: 0.65 To 0.95, P=0.0110) And Patients Whose Tumours Express Pd-L1 (=1%), A Primary Endpoint (Hr 0.64, 95% Ci: 0.49 To 0.84, P=0.0010).1,2 The Mos Was 12.8 Months (95% Ci: 11.3 To 15.5) With Opdivo Plus Yervoy Versus 10.7 Months (95% Ci: 9.4 To 11.9) With Chemotherapy Alone In All Randomized Patients And 13.7 Months (95% Ci: 11.2 To 17.0) With Opdivo Plus Yervoy Versus 9.1 Months (95% Ci: 7.7 To 10) With Chemotherapy Alone In Patients Whose Tumours Express Pd-L1 (=1%). The Median Pfs In Patients Whose Tumours Express Pd-L1 (=1%), Which Was A Co-Primary Endpoint, Was 4.0 Months (95% Ci: 2.4 To 4.9) For Opdivo Plus Yervoy And 4.4 Months (95% Ci: 2.9 To 5.8) For Chemotherapy Alone (Hr 1.02; 95% Ci: 0.78 To 1.34, P=Not Significant). Per Pre-Specified Analysis, Pfs Did Not Meet Statistical Significance. Median Pfs In The Pd-L1 (=1%) Population Was Not Statistically Significant And Therefore It Was Not Hierarchically Tested In The All Comers Population.Opdivo Alone And Opdivo Plus Yervoy Are Associated With The Following Warnings And Precautions: Severe And Fatal Immune-Mediated Adverse Reactions Including Pneumonitis, Colitis, Hepatitis And Hepatotoxicity, Endocrinopathies, Nephritis And Renal Dysfunction, Dermatologic Adverse Reactions, Other Immune-Mediated Adverse Reactions; Infusion-Related Reactions; Complications Of Allogeneic Hematopoietic Stem Cell Transplantation (Hsct); Embryo-Fetal Toxicity; And Increased Mortality In Patients With Multiple Myeloma When Opdivo Is Added To A Thalidomide Analogue And Dexamethasone, Which Is Not Recommended Outside Of Controlled Clinical Trials.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!